CAPTIVATE Study: Ibrutinib Plus Venetoclax for First-line Treatment of CLL/SLL
MedicalResearch.com Interview with: Prof. Tam Constantine Tam, M.D. Hematologist and Disease Group Lead Low Grade Lymphoma and CLL at Peter MacCallum Cancer Centre Victoria, Australia, and Lead study investigator of CAPTIVATE MedicalResearch.com: What is the background for this study? Response: The Phase 2 CAPTIVATE (PCYC-1142) clinical trial evaluated 164 patients younger than 70 years (median age of 58 years) with previously untreated CLL/SLL. Patients were planned to receive ibrutinib for 3 cycles, followed by 12 cycles of ibrutinib and venetoclax in combination. Ninety percent of patients was able to complete the planned therapy. MRD status was evaluated in PB after 6, 9, and 12 cycles and in BM after 12 cycles of the combination. MedicalResearch.com: What are the main findings? Response: Results showed uMRD – defined as less than 1 CLL cell per 10,000 leukocytes (MRD Read the full article
